Indeed, a recent study showed that the expression of HIF1A, as well as its downstream targets, is significantly reduced in grade II (low-grade diffuse) and III (anaplastic) gliomas harboring mutated IDH1/IDH2.31 The gene discussed is IDH2; the disease is central nervous system cancer.